Treatment of triple negative breast cancer

Abstract

The present invention relates to compositions comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and methods for using the compositions in the treatment of triple negative breast cancer (TNBC) by administering an effective amount of the compositions to a subject. In some instances, the subject is a mammal, including at least one of human, feline, and canine mammals.

We claim: 
     
         1 . A method for treating triple negative breast cancer (TNBC), said method comprising administering to a subject an effective amount of at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method of  claim 1 , wherein said subject is a mammal. 
     
     
         3 . The method of  claim 1 , wherein treating TNBC further comprises inhibiting tumor growth. 
     
     
         4 . A composition comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and further comprising a nonionic surfactant. 
     
     
         5 . The composition of  claim 4 , wherein said nonionic surfactant comprises polyethyleneglycol (15)-hydroxystearate. 
     
     
         6 . The composition of  claim 5 , wherein said composition further comprises an alcohol. 
     
     
         7 . The composition of  claim 4 , wherein the nonionic surfactant is present in an amount of about 0.1% to 1.0%. 
     
     
         8 . The composition of  claim 4 , wherein the pivarubicin is present in an amount of about 0.5-3.0 mg/mL. 
     
     
         9 . The composition of  claim 4 , wherein the pivarubicin is present in an amount of about 1 mg/mL. 
     
     
         10 . The composition of  claim 4 , wherein the benzarubicin is present in an amount of about 0.5-3.0 mg/mL. 
     
     
         11 . The composition of  claim 4 , wherein the benzarubicin is present in an amount of about 1 mg/mL. 
     
     
         12 . The composition of  claim 4 , wherein the pivarubicin is present in an amount of about 0.5-3.0 mg/mL, and wherein the benzarubicin is present in an amount of about 0.5-3.0 mg/mL. 
     
     
         13 . The composition of  claim 4 , wherein said composition is formulated for parenteral administration. 
     
     
         14 . A method for treating triple negative breast cancer (TNBC), said method comprising administering to a subject an effective amount of the composition according to  claim 4 . 
     
     
         15 . The method of  claim 12 , wherein said effective amount is about 0.5-3.0 mg/mL. 
     
     
         16 . The method of  claim 12 , wherein the pivarubicin is present in an amount of about 300-750 mg cumulative dose. 
     
     
         17 . The method of  claim 12 , wherein the benzarubicin is present in an amount of about 300-750 mg cumulative dose. 
     
     
         18 . The method of  claim 12 , wherein the at least one of pivarubicin and benzarubicin is provided in a composition comprising 10% to 30% ethanol and 70% to 90% sterile saline. 
     
     
         19 . The method of  claim 16 , wherein the nonionic surfactant in the composition according to  claim 4  comprises polyethyleneglycol (15)-hydroxystearate. 
     
     
         20 . The method of  claim 12 , wherein the at least one of pivarubicin and benzarubicin is provided in a composition comprising about 20% ethanol and about 80% sterile saline, and further comprising about 0.125% polyethyleneglycol (15)-hydroxystearate.